Today’s leaders are building a stronger, more inclusive future for the industry
Shaping tomorrow
Related Posts
Vedanta’s ulcerative colitis candidate misses phase 2 efficacy target
Company shifts focus to phase 3 VE303 trial in recurrent C. difficile infection Vedanta Biosciences has announced that VE202 failed to meet the primary endpoint […]
FDA expands AVTOZMA IV approval to include cytokine release syndrome
Celltrion’s biosimilar now fully aligned with ACTEMRA IV indications in US Celltrion has received US Food and Drug Administration approval for an expanded indication of […]
ICR awarded $25m by Cancer Grand Challenges to research solid tumours in children
Globally, cancer is currently the most leading cause of death due to disease among children The Institute of Cancer Research (ICR) has announced it has […]